ShockWave Medical price target raised to $310 from $275 at BofA

BofA analyst Travis Steed raised the firm’s price target on ShockWave Medical to $310 from $275 and keeps a Buy rating on the shares after it was posted to clinicaltrials.gov that FORWARD PAD, ShockWave’s pivotal study for Javelin Peripheral, completed enrollment at 75 patients five months faster than expected. The firm thinks the fact that the trial enrolled so quickly is likely a good indicator for commercial uptake and it raised its price target on the shares given rising peer multiples, the analyst tells investors.